ARA-290 12 mg

ARA-290, a small peptide derived from the helix beta domain of erythropoietin (EPO), possesses diverse therapeutic properties separate from its conventional role in stimulating red blood cell production in the bone marrow. EPO, a glycoprotein primarily synthesized in the kidney, demonstrates a range of actions including fostering blood vessel growth, supporting cell survival, influencing blood pressure, and providing neuroprotective effects in diabetic neuropathy. ARA-290 specifically delivers the neuroprotective and pain-relieving benefits associated with EPO while abstaining from the stimulation of red blood cell production[1].

Having successfully concluded phase II trials, ARA-290 is poised to progress into phase III trials, targeting various applications in diabetes and autoimmune sarcoidosis. Presently, the peptide garners significant attention for its efficacy in managing neuropathic pain. Additionally, ongoing research explores its potential as a catalyst for wound repair in chronic diabetes, an immune-modulating agent, and a plausible treatment option for systemic lupus erythematosus (lupus or SLE).